| Literature DB >> 17589569 |
A Ballini1, S Capodiferro, M Toia, S Cantore, G Favia, G De Frenza, F R Grassi.
Abstract
The importance of evidence for every branch of medicine in teaching in order to orient the practitioners among the great amount of most actual scientific information's, and to support clinical decisions, is well established in health care, including dentistry. The practice of evidence-based medicine is a process of lifelong, self-directed, problem-based learning which leads to the need for clinically important information about diagnosis, prognosis, therapy and other clinical and health care issues. Nowadays the practice of dentistry is becoming more complex and challenging because of the continually changing in dental materials and equipments, an increasingly litigious society, an increase in the emphasis of continuing professional development, the information explosion and the consumer movement associated with advances on the Internet. The need for reliable information and the electronic revolution have come together to allow the "paradigm shift" towards evidence-based health care. Recent years have seen an increase in the importance of evidence-based dentistry, aiming to reduce to the maximum the gap between clinical research and real world dental practice. Aim of evidence-based practice is the systematic literature review, which synthesizes the best evidences and provides the basis for clinical practice guidelines. These practice guidelines give a brief review of what evidence-based dentistry is and how to use it.Entities:
Mesh:
Year: 2007 PMID: 17589569 PMCID: PMC1891443 DOI: 10.7150/ijms.4.174
Source DB: PubMed Journal: Int J Med Sci ISSN: 1449-1907 Impact factor: 3.738
Evidence-based Medicine/Dentistry: Levels of Evidence
| Level | Therapy/Prevention, Aetiology/Harm | Prognosis | Diagnosis | Differential diagnosis/symptom prevalence study | Economic and decision analyses |
|---|---|---|---|---|---|
| 1a | SR (with homogeneity*) of RCTs | SR (with homogeneity*) of inception cohort studies; CDR† validated in different populations | SR (with homogeneity*) of Level 1 diagnostic studies; CDR† with 1b studies from different clinical centres | SR (with homogeneity*) of prospective cohort studies | SR (with homogeneity*) of Level 1 economic studies |
| 1b | Individual RCT (with narrow Confidence Interval‡) | Individual inception cohort study with ≥ 80% follow-up; CDR† validated in a single population | Validating** cohort study with good††† reference standards; or CDR† tested within one clinical centre | Prospective cohort study with good follow-up**** | Analysis based on clinically sensible costs or alternatives; systematic review(s) of the evidence; and including multi-way sensitivity analyses |
| 1c | All or none§ | All or none case-series | Absolute SpPins and SnNouts †† | All or none case-series | Absolute better-value or worse-value analyses †††† |
| 2a | SR (with homogeneity* ) of cohort studies | SR (with homogeneity*) of either retrospective cohort studies or untreated control groups in RCTs | SR (with homogeneity*) of Level >2 diagnostic studies | SR (with homogeneity*) of 2b and better studies | SR (with homogeneity*) of Level >2 economic studies |
| 2b | Individual cohort study (including low quality RCT; e.g., <80% follow-up) | Retrospective cohort study or follow-up of untreated control patients in an RCT; Derivation of CDR† or validated on split-sample§§§ only | Exploratory** cohort study with good ††† reference standards; CDR† after derivation, or validated only on split-sample§§§ or databases | Retrospective cohort study, or poor follow-up | Analysis based on clinically sensible costs or alternatives; limited review(s) of the evidence, or single studies; and including multi-way sensitivity analyses |
| 2c | "Outcomes" Research; Ecological studies | "Outcomes" Research | Ecological studies | Audit or outcomes research | |
| 3a | SR (with homogeneity*) of case-control studies | SR (with homogeneity*) of 3b and better studies | SR (with homogeneity*) of 3b and better studies | SR (with homogeneity*) of 3b and better studies | |
| 3b | Individual Case-Control Study | Non-consecutive study; or without consistently applied reference standards | Non-consecutive cohort study, or very limited population | Analysis based on limited alternatives or costs, poor quality estimates of data, but including sensitivity analyses incorporating clinically sensible variations. | |
| 4 | Case-series (and poor quality cohort and case-control studies§§ ) | Case-series (and poor quality prognostic cohort studies***) | Case-control study, poor or non-independent reference standard | Case-series or superseded reference standards | Analysis with no sensitivity analysis |
| 5 | Expert opinion without explicit critical appraisal, or based on physiology, bench research or "first principles" | Expert opinion without explicit critical appraisal, or based on physiology, bench research or "first principles" | Expert opinion without explicit critical appraisal, or based on physiology, bench research or "first principles" | Expert opinion without explicit critical appraisal, or based on physiology, bench research or "first principles" | Expert opinion without explicit critical appraisal, or based on economic theory or "first principles" |
Users can add a minus-sign "-" to denote the level of that fails to provide a conclusive answer because of: EITHER a single result with a wide Confidence Interval (such that, for example, an ARR (Absolute Risk Reduction is the difference in risk between the control group (X) and the treatment group (Y) ) in an RCT is not statistically significant but whose confidence intervals fail to exclude clinically important benefit or harm), OR a Systematic Review with troublesome (and statistically significant) heterogeneity. Such evidence is inconclusive, and therefore can only generate Grade D recommendations.
* By homogeneity we mean a systematic review that is free of worrisome variations (heterogeneity) in the directions and degrees of results between individual studies. Not all systematic reviews with statistically significant heterogeneity need be worrisome, and not all worrisome heterogeneity need be statistically significant. As noted above, studies displaying worrisome heterogeneity should be tagged with a "-" at the end of their designated level.
† Clinical Decision Rule. (These are algorithms or scoring systems which lead to a prognostic estimation or a diagnostic category. )
‡ See note #2 for advice on how to understand, rate and use trials or other studies with wide confidence intervals.
§ Met when all patients died before the Rx became available, but some now survive on it; or when some patients died before the Rx became available, but none now die on it.
§§ By poor quality cohort study we mean one that failed to clearly define comparison groups and/or failed to measure exposures and outcomes in the same (preferably blinded), objective way in both exposed and non-exposed individuals and/or failed to identify or appropriately control known confounders and/or failed to carry out a sufficiently long and complete follow-up of patients. By poor quality case-control study we mean one that failed to clearly define comparison groups and/or failed to measure exposures and outcomes in the same (preferably blinded), objective way in both cases and controls and/or failed to identify or appropriately control known confounders.
§§§ Split-sample validation is achieved by collecting all the information in a single tranche, then artificially dividing this into "derivation" and "validation" samples.
†† An "Absolute SpPin" is a diagnostic finding whose Specificity is so high that a Positive result rules-in the diagnosis. An "Absolute SnNout" is a diagnostic finding whose Sensitivity is so high that a Negative result rules-out the diagnosis.
‡‡ Good, better, bad and worse refer to the comparisons between treatments in terms of their clinical risks and benefits.
††† Good reference standards are independent of the test, and applied blindly or objectively to applied to all patients. Poor reference standards are haphazardly applied, but still independent of the test. Use of a non-independent reference standard (where the 'test' is included in the 'reference', or where the 'testing' affects the 'reference') implies a level 4 study.
†††† Better-value treatments are clearly as good but cheaper, or better at the same or reduced cost. Worse-value treatments are as good and more expensive, or worse and the equally or more expensive.
** Validating studies test the quality of a specific diagnostic test, based on prior evidence. An exploratory study collects information and trawls the data (e.g. using a regression analysis) to find which factors are 'significant'.
*** By poor quality prognostic cohort study we mean one in which sampling was biased in favour of patients who already had the target outcome, or the measurement of outcomes was accomplished in <80% of study patients, or outcomes were determined in an unblinded, non-objective way, or there was no correction for confounding factors.
**** Good follow-up in a differential diagnosis study is >80%, with adequate time for alternative diagnoses to emerge (eg 1-6 months acute, 1 - 5 years chronic)
Grades of Recommendation
| A | consistent level 1 studies |
|---|---|
| consistent level 2 or 3 studies | |
| level 4 studies | |
| level 5 evidence |
"Extrapolations" are where data is used in a situation which has potentially clinical important differences than the original study situation.
Evidence-based Medicine/Dentistry Glossary
| Case-controlled study | involves identifying subjects with a clinical condition (cases) and subjects free from the condition (controls), and investigating if the two groups have similar or different exposures to risk indicator(s) of factor(s) associated with the disease |
|---|---|
| Case-series | report on a series of patients with an outcome of interest. No control group is involved |
| Cohort study | involves identifying two groups (cohorts) of subjects, one that did receive the exposure of interest and another that did not, and following these cohorts forward for the outcome of interest |
| Controlled clinical trial | study that uses the same design features of a randomized controlled clinical trial, but, for reasons beyond the control of the investigators, the subjects are assigned using a non-random process into control or experimental groups |
| Crossover study design | administration of two or more experimental therapies, one after the other in a specified or random order, to the same group of patients |
| Cross-sectional study | observation of a defined population at a single point in time or a specified time interval. Exposure and outcome are measured simultaneously |
| Meta-analysis | review that uses quantitative methods to combine the statistical measures from two or more studies and generates a weighted average of the effect of an intervention, degree of association between a risk factor and a disease, or accuracy of a diagnostic test |
| Randomised controlled clinical trial (RCT) | study that randomises a group of subjects into an experimental group and a control group. The experimental group receives the new intervention and the control group receives a placebo or standard intervention. These groups are followed up for the outcomes of interest |
| Systematic-review (SR) | a process of systematically locating, appraising and synthesising evidence from scientific studies in order to obtain a reliable overview. The aim is to ensure a review process that is comprehensive and unbiased. Findings from systematic reviews may be used for decision-making about research and the provision of health care |
| Absolute Risk Reduction (AAR) | is the difference in risk between the control group (X) and the treatment group (Y). AAR = X - Y |